<DOC>
	<DOCNO>NCT00543114</DOCNO>
	<brief_summary>The purpose study determine safety lenalidomide ( revlimid ) combination fludarabine rituximab determine high dose lenalidomide safely give combination . Lenalidomide drug alters immune system may also interfere development tiny blood vessel help support tumor growth . Lenalidomide approve FDA treatment two different blood cancer call myelodysplastic syndrome multiple myeloma . Lenalidomide also study subject relapse CLL . In research study add lenalidomide well-established initial therapy CLL/SLL .</brief_summary>
	<brief_title>Dose Escalation Study Revlimid With Fludarabine-Rituximab CLL/SLL</brief_title>
	<detailed_description>- Participants treat group ( cohort ) three six subject per cohort . The dose lenalidomide fludarabine increase one cohort next . Regardless treatment cohort , participant receive treatment cycle last 28 day . - For first 3-5 day ( depend group ) , participant treat outpatient basis infusion room Dana-Farber Clinic , fludarabine rituximab . Fludarabine give intravenously 3-5 day . Rituximab give intravenously day 1 28-day cycle . Lenalidomide give orally per day 3 week , follow 1 week rest . - Participants monitor closely study treatment . During first 28 day period ( cycle 1 ) , physical exam routine blood test perform weekly . All participant group must finish first 28-day treatment period proceed next group . Once start study treatment , participant continue six cycle ( cycle 28 day ) combination therapy three drug . During period physical exam routine blood test day 1 treatment cycle , additional blood test day 15 cycle . - When participant complete 6 cycle combination therapy , proceed two additional month lenalidomide alone , 21 28 day . - Disease response evaluate 2 , 6 , 8 month study treatment . The following test procedure perform : Physical exam ; blood test ; CT scan evaluate lymph node ; skin testing ; bone marrow biopsy test show evidence remain CLL baseline bone marrow biopsy positive - Participants physical exam lab work every 3 month long disease remain remission .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>18 year age old Diagnosed BCLL/SLL base standard histologic immunophenotypic criterion describe WHO classification No prior systemic therapy CLL/SLL , include chemotherapy antibody therapy Currently need therapy base 1996 NCIWG criterion Measurable disease ECOG Performance Status 02 Laboratory test result within parameter outline protocol Able take aspirin daily prophylactic anticoagulation Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent document Pregnant breastfeeding female Any condition , include presence abnormal laboratory abnormality , place subject unacceptable risk he/she participate study Use experimental drug therapy within 28 day baseline Known hypersensitivity thalidomide Development erythema nodosum characterize desquamate rash take thalidomide similar drug Prior use lenalidomide Concurrent use anticancer agent treatment Known positive HIV Chronic active Hep B patient prophylactic lamivudine Diagnosis Mantle Cell Lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>Revlimid</keyword>
	<keyword>lenalidomide</keyword>
</DOC>